Intact Vascular’s TOBA II (Tack optimized balloon angioplasty II) clinical trial has completed enrolment. A total of 210 patients have been enrolled in TOBA II at 33 sites in the USA and Europe.
The US Food and Drug Administration (FDA) has granted Humacyte’s Humacyl investigational human acellular vessel (HAV) Regenerative Medicine Advanced Therapy (RMAT) designation.
Updated European Society for Vascular Surgery (ESVS) clinical practice guidelines regarding the management of diseases of the descending thoracic aorta have been published in the European Journal of Vascular and Endovascular Surgery.
The Tsimane people—a forager-horticulturalist population of the Bolivian Amazon—have the lowest reported levels of vascular aging for any population, with coronary atherosclerosis five times less common than in the USA, according to a study published in The Lancet and presented at the American College of Cardiology.
Unfors RaySafe has introduced the RaySafe i3, to its suite of real-time dosimetry products, at the European Society of Radiology in Vienna.
The use of GPS mapping tools has become a cornerstone of modern life. A study published by the Journal of Vascular Surgery has demonstrated the clinical opportunities offered by this revolutionary technology, potentially allowing vascular surgeons to accurately measure the walking capacity of their peripheral artery disease patients.
Scott Trerotola presented the first release of eight-month data from the Lutonix AV trial at the Leipzig Interventional Course (LINC; 24–27 January, Leipzig, Germany) and showed that the drug-coated balloon (Lutonix 035 AV, Bard) is linked with a significantly higher target lesion patency and far fewer reinterventions to maintain the opening in a wide variety of failing arteriovenous fistulas than standard angioplasty. An update of the data will be presented at the Charing Cross International Symposium (25–28 April, London, UK).
The Society of Interventional Radiology (SIR), the American Society of Hematology and 23 other medical societies have released a statement in support of the March for Science on 22 April.
A study published online ahead of print in CardioVascular and Interventional Radiology (CVIR) has demonstrated that at one year, uterine fibroid embolization significantly improves all aspects of sexual function and quality of life for patients who undergo the minimally invasive treatment.
Codman Neuro has announced the acquisition of Neuravi. This acquisition comes after the company’s recent acquisition of Pulsar Vascular, expanding its products for stroke therapy. DePuy Ireland Unlimited Company, an affiliate of Codman Neuro, is the acquiring entity. Financial terms of the transaction were not disclosed.
The Cardiovascular and Interventional Radiological Society of Europe (CIRSE) has launched its CIRSE Registry for LifePearl Microspheres (CIREL), a new European-wide observational study that will gather data on patients with colorectal adenocarcinoma and liver-only or liver-dominant metastatic disease, treated with transarterial chemoembolization (TACE) using LifePearl microspheres (Terumo) loaded with irinotecan in specialist hospitals across Europe.
Gillian Jessurun (Treant Zorggroep, Scheper Hospital Emmen, The Netherlands) has enrolled the first patient in the investigator-initiated MASTER DAPT (Management of patients post bioresorbable polymer stent implantation with an abbreviated DAPT regimen) study, launching the global investigation.
Ivascular has announced the product range extension of its self-expandable stent, iVolution, to 200mm length, in various diameters.
A Sheffield healthcare company has announced a strategic ‘buy out’ from its parent company, BD (Becton, Dickinson and Company), a deal which will see the company independently trade once again as UK Medical Ltd.
A study recently published in Cardiovascular and Interventional Radiology has, for the first time, identified adenomatous-dominant benign prostatic hyperplasia as a predictor of clinical success following prostate artery embolization.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos